Comparison
While Kisspeptin is a key regulator of the hypothalamic–pituitary–gonadal axis, controlling puberty and fertility; kisspeptin-10 also inhibits trophoblast invasion and tumor metastasis in experimental models339199, Liraglutide is approved for type 2 diabetes and weight management, improving glycemic control and inducing weight loss through GLP-1–mediated insulinotropic, glucagonostatic, and appetite-suppressing actions6880.
While Kisspeptin works as a family of peptides (eg, kisspeptin-10, -13, -14, -54) derived from the KISS1 precursor that activate G-protein–coupled receptor KISS1R (GPR54), triggering GnRH release and regulating pubertal onset and reproductive axis activity339199, Liraglutide is a human GLP-1 analog with a single amino-acid substitution (Lys34→Arg) and a C16 palmitoyl fatty acid attached to Lys26 via a glutamate linker, producing a long-acting GLP-1 receptor agonist6880.
Kisspeptin is 10 amino acids long, whereas Liraglutide is longer as it has a length of 31 amino acids. Kisspeptin is made up of a sequence of Tyrosine, Asparagine, Tryptophan, Asparagine, Serine, Phenylalanine, Glycine, Leucine, Arginine, Tyrosine. Liraglutide is made up of a sequence of sequence data not available in the current dataset.
Kisspeptin
KISS1
Liraglutide
GCG